The latest trial showed that people with recurrent, especially treatment-resistant depression, also feature an elevated level of IL-17, which can become an additional diagnostic marker of treatment-resistant depression (Gałecka et al., 2021; Nothdurfter et al., 2021). Here, IL17A is linked to major depressive disorder.